From Wikipedia, the free encyclopedia
  (Redirected from R-ESHAP)
Jump to navigation Jump to search

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]

[R]-ESHAP consists of:

  1. (R)ituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
  2. (E)toposide, an epipodofyllotoxin topoisomerase inhibitor
  3. (S)olu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
  4. (H)igh-dose (A)ra-C - cytarabine
  5. (P)latinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 0
(E)toposide 40 mg/m2 IV infusion over 1 hr Days 1-4
(S)olu-Medrol - Methylprednisolone 500 mg IV bolus over 15 min Days 1-5
(H)igh-dose (A)ra-Ccytarabine 2000 mg/m2 IV infusion over 2 hrs Day 5
Platinol (cisplatin) 25 mg/m2 IV continuous infusion over 24 hrs Days 1-4